Select Publications

Journal articles

Kok PS; Chan B; Zhang A; O'Byrne K; Aberoumoud M; Thavaneswaran S; Lin FP; Kansara M; Corpuz T; Wheeler P; Simes J; Thomas DM; Lee CK, 2025, '181P Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma', Annals of Oncology, 36, pp. s1816, http://dx.doi.org/10.1016/j.annonc.2025.10.1018

Kansara M; Lin FP; Thavaneswaran S; Huang ML; Tran M; Corpuz T; Lu J; Espinoza D; Chinchen S; Ballinger M; Grimison P; Andelkovic V; Dow EG; Desai J; Simes J; Thomas D, 2025, '2715P Phase II trial of tildrakizumab in treatment-refractory bone and soft tissue sarcomas', Annals of Oncology, 36, pp. s1447, http://dx.doi.org/10.1016/j.annonc.2025.08.3325

Gaughran G; Zaheed M; Harris SJ; Napier C; Yap M; Bellinger M; Grady J; Kee D; Caillet V; Davies A; Thavaneswaran S; Thomas DM, 2025, '777P HIF2α pathway aberrations across tumour types: A rare but actionable entity with high germline conversion', Annals of Oncology, 36, pp. s1990, http://dx.doi.org/10.1016/j.annonc.2025.10.1192

Gaughran G; Mamrot J; Fitzgerald S; Kee D; Napier C; Harris SJ; Thavaneswaran S; Grady J; Davies A; Bellinger M; Thomas DM, 2025, '797P Real-world experience of liquid biopsy (LBx) vs tissue-based comprehensive genomic profiling (tCGP)', Annals of Oncology, 36, pp. s1995 - s1996, http://dx.doi.org/10.1016/j.annonc.2025.10.1211

Gaughran G; Body A; Thavaneswaran S; Bellinger M; Harris SJ; Davies AG; Huang ML; Kee D; Thomas D, 2025, '82P Y220C, a rare but druggable TP53 mutation: A molecular landscape in an Australian context', ESMO Open, 10, pp. 105432, http://dx.doi.org/10.1016/j.esmoop.2025.105432

Lin FP; Itchins M; Chinchen S; Thavaneswaran S; Mersiades A; Aberoumand M; Nagrial A; Xu W; Takhar HS; Harrup RA; Desai J; Cummins M; Espinoza D; Kansara M; Yip S; Lee CK; Simes J; Solomon BJ; Pavlakis N; Thomas D, 2025, '996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14', Annals of Oncology, 36, pp. s651, http://dx.doi.org/10.1016/j.annonc.2025.08.1565

Zhu Y; Lin FP-Y; So JY; Oh EW; Philipsen S; Thomas DM; Grady JP; Lawrence BJ; Wilson MK, 2025, 'Actionability of genomic alterations in the Molecular Screening and Therapeutics (MoST) program in New Zealand (NZ) depending on residence in NZ or Australia.', Journal of Clinical Oncology, 43, pp. e13763 - e13763, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e13763

Spencer S; Ye W; Napier C; Lin FP-Y; Thomas DM; Chan R; Ballinger ML; Morton RL; Berber S; Zou D; Peng S, 2025, 'Clinical and economic value of comprehensive genomic profiling in patients with advanced solid cancers using Australian real-world data: Preliminary analyses.', Journal of Clinical Oncology, 43, pp. e15084 - e15084, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e15084

Lin FP-Y; Goldstein D; Grady JP; Napier C; Thavaneswaran S; Pitiyarachchi O; Kansara M; Chantrill LA; Sjoquist K; Thornton K; Raina A; Magenau A; Simes J; Ballinger ML; Sharbeen G; Timpson P; Pajic M; Phillips P; Thomas DM, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', Journal of Clinical Oncology, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4120

Ballinger M; Zaheed M; Carpenter E; Napier C; Cops E; Ferris N; Moodie K; Milner B; Moses D; Dwarte T; Poplawski N; Dow E; Tucker K; Trainer A; James P; Thomas D, 2025, 'LONG TERM SURVEILLANCE OUTCOMES IN SARCOMA PREDISPOSITION SYNDROMES', ESMO Rare Cancers, 4, pp. 100044, http://dx.doi.org/10.1016/j.esmorc.2025.100044

Lin FP-Y; Huang ML; Grady JP; Thavaneswaran S; Kansara M; Napier C; Ballinger ML; Simes J; Thomas DM, 2025, 'Machine learning–based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 43, pp. e13683 - e13683, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e13683

Pavlakis N; Lee CK; Ballinger ML; Brown CSB; Grady JP; Lin F; Thavaneswaran S; Mersiades AJ; Zhou DD-X; Lee J; John T; Napier CE; Cummins MM; Collignon E; Sebastian L; Turnbull OMH; Simes J; Thomas DM; Solomon BJ, 2025, 'P2.06.61 ASPiRATION. Australian Nationwide Cohort Study to Assess Impact of Comprehensive Genomic Profiling in Metastatic Lung Cancer', Journal of Thoracic Oncology, 20, pp. s318 - s319, http://dx.doi.org/10.1016/j.jtho.2025.09.595

Kohlmann W; Curtin K; Madsen MJ; Camp NJ; Jeter JM; Ballinger ML; Thomas DM; Garber JE; Schiffman JD, 2025, 'Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria.', Journal of Clinical Oncology, 43, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11570

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Collet L; Telouk P; Albarede F; Girodet M; Maqua C; Rogasik M; Ducimetière F; Tabone-Eglinger S; Brahmi M; Dufresne A; Thomas DM; Ballinger ML; Blay JY; Ray-Coquard I, 2024, 'Connecting the changing trace elements spectrum and survival in sarcoma: a pilot study', Metabolomics, 20, http://dx.doi.org/10.1007/s11306-024-02178-z

Takeda K; Nakayama M; Hayakawa Y; Kojima Y; Ikeda H; Imai N; Ogasawara K; Okumura K; Thomas DM; Smyth MJ, 2024, 'Correction to: IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting (Nature Communications, (2017), 8, 1, (14607), 10.1038/ncomms14607)', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-53456-2

Deng F; Li Y; Yang B; Sang R; Deng W; Kansara M; Lin F; Thavaneswaran S; Thomas DM; Goldys EM, 2024, 'Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing', Nature Communications, 15, pp. 1818, http://dx.doi.org/10.1038/s41467-024-46001-8

Gianferante DM; Moore A; Spector LG; Wheeler W; Yang T; Hubbard A; Gorlick R; Patiño-Garcia A; Lecanda F; Flanagan AM; Amary F; Andrulis IL; Wunder JS; Thomas DM; Ballinger ML; Serra M; Hattinger C; Demerath E; Johnson W; Birmann BM; De Vivo I; Giles G; Teras LR; Arslan A; Vermeulen R; Sample J; Freedman ND; Huang WY; Chanock SJ; Savage SA; Berndt SI; Mirabello L, 2024, 'Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma', Cancer Epidemiology, 92, http://dx.doi.org/10.1016/j.canep.2023.102432

Best MC; Butow P; Savard J; Newson AJ; Campbell R; Vatter S; Napier CE; Bartley N; Tucker K; Ballinger ML; Thomas DM; Butow P; Tucker K; Juraskova I; Schlub T; Davies G; Meiser B; Goldstein D, 2024, 'From ownership to custodianship of tumor biopsy tissue in genomic testing: A mixed methods study of patient views', Oncologist, 29, pp. e1169 - e1179, http://dx.doi.org/10.1093/oncolo/oyae074

Dziadziuszko R; Barlesi F; Kim JE; Gadgeel SM; Krzakowski M; Jeong JH; Daniele G; Chen D; Hu Y; Wilson TR; Simmons BP; Thomas DM, 2024, 'Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.', Journal of Clinical Oncology, 42, pp. lba2509 - lba2509, http://dx.doi.org/10.1200/jco.2024.42.17_suppl.lba2509

Barjesteh van Waalwijk van Doorn-Khosrovani S; Kholmanskikh Van Criekingen O; Koole S; Thomas DM; Gelderblom H, 2024, 'Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development', Cancer Cell, 42, pp. 923 - 929, http://dx.doi.org/10.1016/j.ccell.2024.05.014

Thomas DM; Daniele G; Kim JE; Gadgeel SM; Ahn ER; Paz-Ares LG; Prenen H; Chen D; Fang J; Wilson TR; Simmons BP; Barlesi F, 2024, 'Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study.', Journal of Clinical Oncology, 42, pp. 3092 - 3092, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.3092

Kim JE; Thomas D; Gadgeel S; Corassa M; Tan TJ; Girda E; Richards D; Tejpar S; Chen D; Fang J; Patel S; Wilson TR; Barlesi F, 2024, 'Abstract CT265: Trastuzumab emtansine in patients (pts) with HER2 mutation-positive (HER2 mut ) tumors: TAPISTRY study', Cancer Research, 84, pp. ct265 - ct265, http://dx.doi.org/10.1158/1538-7445.am2024-ct265

Mirabello L; Egolf LE; Zhu B; Gianferante DM; Wang K; Li SA; Machiela MJ; Spector LG; Schiffman JD; Sabo A; Renwick A; Martin-Giacalone B; Scheurer ME; Plon S; Hawkins D; Venkatramani R; Stewart D; Morton LM; Hudson MM; Armstrong GT; Bhatia S; Dean M; Janeway KA; Patiño-Garcia A; Lecanda F; Serra M; Hattinger C; Scotlandi K; Flanagan AM; Amary F; Andrulis IL; Wunder JS; Ballinger ML; Thomas DM; Delattre O; Hubbard AK; Liu J; Luo W; Hicks BD; Yeager M; Rafati M; Huang W-Y; Landi MT; Lori A; Diver R; Savage SA; Chanock SJ; Lupo PJ, 2024, 'Abstract 775: Underlying germline genetic architecture of pediatric sarcomas: Evaluating the role of common and rare variants in 4,160 patients', Cancer Research, 84, pp. 775 - 775, http://dx.doi.org/10.1158/1538-7445.am2024-775

Freeman B; Peters MJ; Bittoun R; Brightwell R; English DR; Thomas DP; Otlowski MFA; Zwar NA; Chamberlain C, 2024, 'National Health and Medical Research Council statement on electronic cigarettes: 2022 update', Medical Journal of Australia, 220, pp. 100 - 106, http://dx.doi.org/10.5694/mja2.52163

Ringborg U; von Braun J; Celis J; Baumann M; Berns A; Eggermont A; Heard E; Heitor M; Chandy M; Chen CJ; Costa A; De Lorenzo F; De Robertis EM; Dubee FC; Ernberg I; Gabriel M; Helland Å; Henrique R; Jönsson B; Kallioniemi O; Korbel J; Krause M; Lowy DR; Michielin O; Nagy P; Oberst S; Paglia V; Parker MI; Ryan K; Sawyers CL; Schüz J; Silkaitis K; Solary E; Thomas D; Turkson P; Weiderpass E; Yang H, 2024, 'Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023', Molecular Oncology, 18, pp. 245 - 279, http://dx.doi.org/10.1002/1878-0261.13575

Mersiades AJ; Solomon Benjamin J; Thomas David M; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OMH; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N, 2024, 'ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue', Future Oncology, 20, pp. 361 - 371, http://dx.doi.org/10.2217/fon-2023-0366

Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; Investigators KCF; James PA; Spurdle AB, 2024, 'Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00453

Cho D; Lord SJ; Ward R; IJzerman M; Mitchell A; Thomas DM; Cheyne S; Martin A; Morton RL; Simes J; Lee CK, 2024, 'Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework', Therapeutic Advances in Medical Oncology, 16, http://dx.doi.org/10.1177/17588359241273062

Sargen MR; Kim J; Haley JS; Barker HP; Mundra PA; Ballinger ML; Thomas DM; Carey DJ; Goldstein AM; Stewart DR, 2024, 'Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans', Genetics in Medicine Open, 2, http://dx.doi.org/10.1016/j.gimo.2024.101895

Klein O; Carlino M; Brown M; Harris SJ; Gunjur A; Underhill CR; Zielinski R; Kee D; Lam W-S; Chan H; Harrup RA; So J; Collins I; Michael M; Torres J; Palmer JB; Thomas D; Wilkie K; Cebon J; Nagrial A, 2024, '282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer', Annals of Oncology, 35, pp. s119, http://dx.doi.org/10.1016/j.annonc.2024.05.288

Klein O; Carlino MS; Michael M; Underhill CR; So J; Kee D; Antill Y; Lam W-S; Chan H; Harrup RA; Hamilton A; Palmer JB; Thomas DM; Wilkie K; Cebon J; Gao B, 2024, '713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial', Annals of Oncology, 35, pp. s546 - s547, http://dx.doi.org/10.1016/j.annonc.2024.08.775

Klein O; Gao B; Chan H; Michael M; Zielinski R; So J; Harris SJ; Kee D; Collins IM; Lam W-S; Lyle M; Underhill CR; Brown M; Harrup RA; Wong SF; Palmer JB; Thomas D; Wilkie K; Cebon J; Carlino MS, 2024, '998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study', Annals of Oncology, 35, pp. s679 - s680, http://dx.doi.org/10.1016/j.annonc.2024.08.1057

Walpole IR; Zaman FY; Zhao P; Marshall VM; Lin FP; Thomas DM; Shackleton M; Antolin AA; Ameratunga M, 2024, 'Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases', Clinical and Translational Medicine, 14, pp. e1657, http://dx.doi.org/10.1002/ctm2.1657

Pavlakis N; Kichenadasse G; Richardson G; Bowyer S; Andelkovic V; Ganju V; Tan A; Samol J; Thomas D; Fernandez AM; Paszkiewicz K; Ingram P; Boyd-Kirkup J; Kwek KY, 2024, 'P3.12D.09 Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous Non-Small Cell Lung Cancer', Journal of Thoracic Oncology, 19, pp. s350, http://dx.doi.org/10.1016/j.jtho.2024.09.631

Sharaf R; Jin DX; Grady J; Napier C; Ebot E; Frampton GM; Albacker LA; Thomas DM; Montesion M, 2023, 'A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content', Npj Genomic Medicine, 8, http://dx.doi.org/10.1038/s41525-023-00369-6

Lu CY; Terry V; Thomas DM, 2023, 'Precision medicine: affording the successes of science', Npj Precision Oncology, 7, http://dx.doi.org/10.1038/s41698-022-00343-y

Vaghjiani VG; Cochrane CR; Jayasekara WSN; Chong WC; Szczepny A; Kumar B; Martelotto LG; McCaw A; Carey K; Kansara M; Thomas DM; Walkley C; Mudge S; Gough DJ; Downie PA; Peacock CD; Matsui W; Watkins DN; Cain JE, 2023, 'Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype', Oncogene, 42, pp. 3529 - 3541, http://dx.doi.org/10.1038/s41388-023-02864-7

McNamee N; Lin F; Sim H-W; Napier C; Thomas D; Simes J; Thavaneswaran S, 2023, 'PATH-25. EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', Neuro-Oncology, 25, pp. v173 - v173, http://dx.doi.org/10.1093/neuonc/noad179.0655

Le Tourneau C; André F; Helland Å; Mileshkin L; Minnaard W; Schiel A; Taskén K; Thomas DM; Veronese ML; Durán-Pacheco G; Leyens L; Rufibach K; Thomas M; Krämer A, 2023, 'Modified study designs to expand treatment options in personalised oncology: a multistakeholder view', European Journal of Cancer, 194, http://dx.doi.org/10.1016/j.ejca.2023.113278

Ng JY; Warwick L; Craft P; Austen L; Ashford B; Gorddard N; Ballinger ML; Thomas DM; Blombery P; Tucker K; Polizzotto MN, 2023, 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature', British Journal of Haematology, 203, pp. 481 - 484, http://dx.doi.org/10.1111/bjh.19059

Zeverijn LJ; Looze EJ; Thavaneswaran S; van Berge Henegouwen JM; Simes RJ; Hoes LR; Sjoquist KM; van der Wijngaart H; Sebastian L; Geurts BS; Lee CK; de Wit GF; Espinoza D; Roepman P; Lin FP; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; de Vos FYFL; van Herpen CML; Gelderblom H; Verheul HMW; Thomas DM; Voest EE, 2023, 'Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials', International Journal of Cancer, 153, pp. 1413 - 1422, http://dx.doi.org/10.1002/ijc.34649

Harrison C; Bartley N; Jacobs C; Best M; Vatter S; Meiser B; Ballinger ML; Thomas DM; Butow P, 2023, 'Family communication and results disclosure after germline sequencing: A mixed methods study', Patient Education and Counseling, 114, http://dx.doi.org/10.1016/j.pec.2023.107800

Sabesan S; Malica M; Gebbie C; Scott C; Thomas D; Zalcberg J, 2023, 'Implementation of the Australasian Teletrial Model: Translating ideas into action using implementation science frameworks', Journal of Telemedicine and Telecare, 29, pp. 641 - 647, http://dx.doi.org/10.1177/1357633X211017805

Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0

Zeverijn LJ; Looze E; Thavaneswaran S; van Berge Henegouwen JM; Simes J; Hoes LR; Geurts B; Sebastian L; Roepman P; Lin FP-Y; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; De Vos FYFL; Verheul HMW; Gelderblom H; Thomas DM; Voest EE; Sjoquist KM, 2023, 'Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.', Journal of Clinical Oncology, 41, pp. 3101 - 3101, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3101

Kansara M; Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 41, pp. 4093 - 4093, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4093

Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Kansara M; Sebastian L; Kee D; Zaheed M; Millward M; Brown MP; Charakidis M; Craft PS; Grimison PS; Harrup RA; O'Byrne KJ; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.', Journal of Clinical Oncology, 41, pp. 1540 - 1540, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1540

Zaheed M; Napier CE; Cops EJ; Ferris N; Moodie K; Milner B; Moses D; Poplawski N; Dow EG; Harris M; Tucker K; Trainer A; James P; Thomas DM; Ballinger ML, 2023, 'Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.', Journal of Clinical Oncology, 41, pp. 10578 - 10578, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10578


Back to profile page